One of the few bright spots in Boston’s life-science lab space market this year has dimmed.

Ginkgo Bioworks reported mixed Q3, with a $45M one-time revenue boost masking underlying revenue growth issues. Read why I ...

Ginkgo Bioworks is offering its newly-completed Boston Seaport lab complex for sublease as it shrinks its real estate ...

Revenue exceeded analyst estimates by 98%. Earnings per share (EPS) also surpassed analyst estimates by 67%. Looking ahead, ...

BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $6 from $7 and keeps a Sell rating on the shares ...

Boston-based Ginkgo Bioworks has canceled plans to move into a 250K SF lab data center and will exit two Cambridge locations ...

Ginkgo Bioworks is headquartered at 27 Drydock Avenue in Boston's Seaport. Ginkgo has canceled its planned move into a ...

Boston: Ginkgo Bioworks has announced the completion of the first milestone of a previously announced partnership with Merck, ...

Ginkgo Bioworks Holdings, Inc. ( (DNA)) has released its Q3 earnings. Here is a breakdown of the information Ginkgo Bioworks Holdings, Inc. presented to its investors. Ginkgo Bioworks Holdings, Inc.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder ...

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of 55% and 102.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?